Desloratadine partially inhibits the augmented bacterial responses in the sinuses of allergic and infected mice
- 1 October 2004
- journal article
- Published by Wiley in Clinical and Experimental Allergy
- Vol. 34 (10) , 1649-1654
- https://doi.org/10.1111/j.1365-2222.2004.02059.x
Abstract
Allergic rhinitis (AR) is considered a major predisposing factor for the development of acute bacterial rhinosinusitis. How AR augments a bacterial infection is unknown. Our purpose in this study was to test whether an H1 receptor antagonist, desloratadine, could reduce the augmented effect of an ongoing allergic reaction on acute bacterial rhinosinusitis. Three groups of infected and ovalbumin (OVA)-sensitized mice were studied: (1) infected and allergic mice treated with desloratadine, (2) infected and allergic mice treated with placebo, and (3) infected mice. A fourth group of uninfected, non-sensitized mice served as a control for the cellular changes. BALB/c mice were sensitized by two intraperitoneal injections of OVA given 8 days apart. One day after the second injection, the mice were nasally exposed daily to 6% OVA (the groups treated with desloratadine or placebo) or phosphate-buffered saline (PBS) (the infection-only group) for 5 days. After the second OVA exposure, the mice were intranasally inoculated with Streptococcus pneumoniae. Desloratadine or placebo was given daily throughout the OVA exposure period. Nasal allergic symptoms were observed by counting of nasal rubbing and sneezing for 10 min after OVA or PBS nasal challenge. On day 5 post-infection, nasal lavage culture was done, and the inflammatory cells in the sinuses were evaluated by flow cytometry. Mice that were made allergic, infected, and treated with placebo showed more organisms and phagocytes than did only infect mice. They also manifested allergic nasal symptoms and eosinophil influx into the sinuses. Desloratadine treatment during allergen exposure reduced allergic symptoms and reduced sinonasal infection (P<0.05). There tended to be less myeloid cell and neutrophil influx (P=0.09 both), but not eosinophil influx (P=0.85) compared with that in the placebo-treated group. Desloratadine treatment during nasal challenge inhibited allergic symptoms and reduced sinonasal infection, suggesting that histamine via an H1 receptor plays a role in the augmented infection in mice with an ongoing allergic reaction.Keywords
This publication has 29 references indexed in Scilit:
- Issues in the management of bacterial sinusitisOtolaryngology -- Head and Neck Surgery, 2002
- Desloratadine reduces allergen challenge-induced mucinous secretion and plasma exudation in allergic rhinitisAnnals of Allergy, Asthma & Immunology, 2002
- Allergy and Allergic DiseasesNew England Journal of Medicine, 2001
- A whole-blood flow cytometric assay for leukocyte CD11b expression using fluorescence signal triggeringEuropean Journal of Haematology, 2000
- Rhinovirus infections: induction and modulation of airways inflammation in asthmaClinical and Experimental Allergy, 1999
- Rhinitis and inhalant allergensPublished by American Medical Association (AMA) ,1997
- Chemokine-induced eosinophil recruitment. Evidence of a role for endogenous eotaxin in an in vivo allergy model in mouse skin.Journal of Clinical Investigation, 1997
- Flow cytometric identification of murine neutrophils and monocytesJournal of Immunological Methods, 1996
- Allergen-induced increase in nonspecific nasal reactivity is blocked by antihistamines without a clear-cut relationship to eosinophil influxJournal of Allergy and Clinical Immunology, 1990
- Allergy in patients with acute maxillary sinusitisAllergy, 1989